Verve Therapeutics, Inc. (NASDAQ:VERV - Get Free Report)'s share price was down 4.9% on Monday . The stock traded as low as $7.84 and last traded at $7.76. Approximately 241,410 shares changed hands during mid-day trading, a decline of 85% from the average daily volume of 1,634,615 shares. The stock had previously closed at $8.16.
Analyst Upgrades and Downgrades
A number of equities research analysts have commented on the company. Canaccord Genuity Group lifted their target price on Verve Therapeutics from $29.00 to $32.00 and gave the company a "buy" rating in a research report on Wednesday, November 6th. Royal Bank of Canada reduced their price objective on shares of Verve Therapeutics from $20.00 to $17.00 and set an "outperform" rating on the stock in a report on Wednesday, November 6th. Finally, HC Wainwright lowered their target price on shares of Verve Therapeutics from $15.00 to $14.00 and set a "buy" rating for the company in a research note on Wednesday, November 6th.
Get Our Latest Research Report on VERV
Verve Therapeutics Price Performance
The firm has a market cap of $652.76 million, a PE ratio of -3.13 and a beta of 1.74. The company's 50 day moving average price is $6.59 and its 200 day moving average price is $5.90.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently bought and sold shares of the stock. GAMMA Investing LLC increased its stake in Verve Therapeutics by 189.7% in the fourth quarter. GAMMA Investing LLC now owns 6,054 shares of the company's stock valued at $34,000 after purchasing an additional 3,964 shares during the last quarter. IFP Advisors Inc increased its position in shares of Verve Therapeutics by 823,700.0% in the fourth quarter. IFP Advisors Inc now owns 8,238 shares of the company's stock valued at $47,000 after buying an additional 8,237 shares in the last quarter. Creative Planning acquired a new position in Verve Therapeutics during the third quarter worth about $50,000. PFG Investments LLC acquired a new stake in shares of Verve Therapeutics during the third quarter valued at $53,000. Finally, Erste Asset Management GmbH purchased a new stake in shares of Verve Therapeutics during the third quarter worth about $56,000. 97.11% of the stock is currently owned by hedge funds and other institutional investors.
About Verve Therapeutics
(
Get Free Report)
Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.
Recommended Stories
Before you consider Verve Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Verve Therapeutics wasn't on the list.
While Verve Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
